Right heart catheterisation is still a fundamental part of the follow-up assessment of pulmonary arterial hypertension
作者: Marc HumbertJason Weatherald
作者单位: 1Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France
2Service de Pneumologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
3INSERM UMR S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France
4University of Calgary, Dept of Medicine, Division of Respirology, Calgary, AB, Canada
5Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada
刊名: European Respiratory Journal, 2018, Vol.52 (1)
来源数据库: European Respiratory Society
DOI: 10.1183/13993003.00738-2018
原始语种摘要: For patients with pulmonary arterial hypertension (PAH), the most recent European guidelines state that right heart catheterisation (RHC) is mandatory for confirming the diagnosis of PAH, and that RHC should be considered 3–6 months after therapy changes and in patients who experience clinical deterioration [1, 2]. The guidelines also mention that some centres perform RHC at regular intervals during follow-up [1, 2]. However, many centres across the world do not routinely monitor invasive haemodynamic variables during follow-up, for a variety of potential reasons including the invasive nature of the test, cost or availability. We argue that, based on current data, RHC is still an indispensable component of the clinical management and follow-up of PAH patients in the current treatment era.
全文获取路径: ERS 

  • follow 
  • hypertension 高血压
  • arterial 动脉的
  • treatment 处理
  • still 
  • perform 履行
  • pulmonary 肺的
  • fundamental 基本的
  • availability 有效度
  • during 在的期间